Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Egetis Therapeutics AB's Revenue for the
three
months ended in Mar. 2026 was kr13.40 Mil. Egetis Therapeutics AB's average Accounts Receivable for the
three
months ended in Mar. 2026 was kr12.20 Mil.
Hence, Egetis Therapeutics AB's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.10.
Egetis Therapeutics AB (LTS:0ABW) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Egetis Therapeutics AB Receivables Turnover Related Terms
Egetis Therapeutics AB Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Egetis Therapeutics AB's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0ABW vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Egetis Therapeutics AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egetis Therapeutics AB Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Egetis Therapeutics AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egetis Therapeutics AB (LTS:0ABW) has a Receivables Turnover of 1.10 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Egetis Therapeutics AB and its competitors. According to the industry distribution chart, Egetis Therapeutics AB ranks #642 out of 841 companies in the Biotechnology industry, placing it in the top 76.3%.
Is Egetis Therapeutics AB's Receivables Turnover too high?
Egetis Therapeutics AB's current Receivables Turnover is 1.10. The Biotechnology industry median Receivables Turnover is 5.27. Egetis Therapeutics AB's value of 1.10 is 79.1% below this industry median. Based on the distribution chart, Egetis Therapeutics AB ranks #642 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Egetis Therapeutics AB has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Egetis Therapeutics AB ranks #642 out of 841 companies for Receivables Turnover. This places Egetis Therapeutics AB in the lower half of its industry. The industry median Receivables Turnover is 5.27. Egetis Therapeutics AB's value of 1.10 is 79.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egetis Therapeutics AB's current Receivables Turnover of 1.10 is 79.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Egetis Therapeutics AB and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egetis Therapeutics AB's current Receivables Turnover is 1.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (LTS:0ABW) is currently considered Modestly Overvalued. The stock's GF Value™ is kr5.64, compared to a current price of kr6.27 — trading 11.2% above its estimated fair value. The current Receivables Turnover is 1.10 and 79.1% below the Biotechnology industry median of 5.27. Egetis Therapeutics AB's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Egetis Therapeutics AB (LTS:0ABW), the current Receivables Turnover is 1.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egetis Therapeutics AB (LTS:0ABW) Overvalued in 2026?
Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued.
The current stock price of kr6.27 is trading 11.2% above its estimated GF Value™ of kr5.64.
GuruFocus considers Egetis Therapeutics AB to be Modestly Overvalued.
Key valuation signals for LTS:0ABW:
Receivables Turnover: 1.10
GF Value™: kr5.64 vs. price of kr6.27 (11.2% above fair value)
Industry Position: 79.1% below the Biotechnology median (#642 of 841)
No single metric tells the full story. See the LTS:0ABW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
69GF Score
Get the complete analysis for LTS:0ABW
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0ABW has been successfully added to your 
